

FORM PTO 1449 (modified)	Atty. Docket No. X11057C	Serial No 10/785,326
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	First Applicant Cohen	
	Application Date February 24, 2004	Group Art Unit 1614

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. 1	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Pages or Relevant Figures Appear
	AA	US RE39,049 E	March 28, 2006	Black	
	AB	US			

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. 1	Foreign Patent Document Country Code <sup>3</sup> -Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	BA					
	BB					

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher, city and/or country where published.	T <sup>6</sup>
	CA	CUMMINGS et al., The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women – Results From the MORE Randomized Trial, Journal of the American Medical Association (1999) pg 2189-2197, Vol. 281, No. 23.	
	CB	MARTINO et al., Continuing Outcomes Relevant to Evista: Breast Cancer Incidence in Postmenopausal Osteoporotic Women in a Randomized Trial of Raloxifene, Journal of the National Cancer Institute (2004) pg 1751-1761, Vol. 96, No. 23.	
	CC	BARRETT-CONNER, et al., The New England Journal of Medicine, Effects of Raloxifene on Cardiovascular Events and Breast Cancer in Postmenopausal Women (2006) pg. 125-137, Vol. 355, No. 2.	
	CD	VOGEL et al., Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease Outcomes - The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial, Journal of the American Medical Association (2006) pg 2727-2741, Vol. 295, No. 23.	
	CE	LIPPMAN, et al., Effect of Raloxifene on the Incidence of Invasive Breast Cancer in Postmenopausal Women with Osteoporosis Categorized by Breast Cancer Risk (2006) pg. 5242-5247, Vol. 12, No. 17.	

Examiner Signature	Date Considered
-----------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language translation is attached. Burden Hours Statement: This form is estimated to take 2-3 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.